ANT-GROUP
5.3.2024 12:28:33 CET | Business Wire | Press release
For the third consecutive year, Ant Group, a global digital technology provider, has been recognized as a Top 100 Global Innovator™ 2024 by Clarivate™, a global leader in connecting people and organizations to intelligence they can trust to transform their world. This recognition reaffirms Ant Group's ongoing commitment to innovation excellence in technologies such as artificial intelligence (AI) and blockchain.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305020027/en/
Clarivate recognizes Ant Group as one of the Top 100 Global Innovators 2024 (Graphic: Business Wire)
Gordon Samson, President, Intellectual Property, Clarivate, said, “We congratulate Ant Group for being named as a Top 100 Global Innovator again. To feature as a Top 100 Global Innovator is no mean feat as maintaining an edge in the innovation ecosystem is harder than ever. Organizations must balance experimentation and risk with discipline and reward. We measure and rank innovative performance in a dynamic and thorough way, using live thresholds of differentiation. At Clarivate, we think forward by analyzing the quality of ideas, their potency and their impact to identify the world’s top innovators, and this year we reveal the ranking of these innovators for the first time.”
As of the end of 2023, Ant Group had filed 32,459 patent applications globally, with 22,102 patents granted. The top three categories of these patent applications are security technology, blockchain and AI.
"Our recognition by Clarivate as one of the Top 100 Global Innovators is a testament to our innovation capabilities," said Shen PAN, Director of Patents at Ant Group. "We are committed to leveraging technology to build trust and accelerate digital transformation across industries. Our journey is driven by our advancements in key technologies such as blockchain, privacy computing, security technology, Internet of Things (IoT) databases, and most notably, AI.”
In the field of AI, Ant Group has been continuously leveraging its technology to enhance the user experience across its product offerings for years. As of the end of 2023, Ant Group had filed over 3,000 AI-related patents. During Alipay’s 2024 Chinese New Year campaign, AI features in the app attracted 600 million interactions.
To facilitate technological advancement across industries, Ant Group has been making its innovations publicly accessible to developers in the open-source community. For example, Ant Group’s AI infrastructure team open-sourced ATorch, an extension library of PyTorch, that can improve GPU utilization rate up to 60% in large-scale pre-trainings of Large Language Models (LLMs). Meanwhile, the company’s open-sourced Lookahead achieves lossless generation accuracy for LLMs while boosting the inference speeds of LLMs by 2 to 6 times.
By the end of 2023, the number of open-source repositories from Ant Group on platforms such as GitHub had exceeded 1,900. Additionally, according to the 2023 Blue Paper on the Development of Open Source in China published by China OSS Promotion Union (COPU), Ant Group is recognized as one of the top three organizations in the country in terms of open-source contributions and influence.
Leveraging its innovations in technologies such as blockchain, privacy computing, security technology, IoT, and databases, Ant Group provides technology products and services to support the digital transformation and collaboration of global enterprise customers across a variety of industries. These industries include banking, telecommunication, real estate, medicine and energy. The company has garnered recognition from various organizations for its excellence in delivering innovative products and services to customers. For example, AntChain was recognized by Forbes on the Blockchain 50 list for five consecutive years (from 2019 to 2023). In September 2023, ZOLOZ was named as a Representative Vendor for the second consecutive time in the latest Gartner Market Guide for Identity Verification.
Methodology
The Top 100 Global Innovators uses a complete comparative analysis of global invention data to assess the strength of every patented idea, using measures tied directly to their innovative power.
To move from the individual idea strength to identify the organizations that create them more consistently and frequently, Clarivate sets two threshold criteria that potential candidates must meet and then adds a measure of their patented innovation output over the past five years.
For full information on the methodology used to identify the 2024 list, see here.
About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com
About Ant Group
Ant Group traces its roots back to Alipay, which was established in 2004 to create trust between online sellers and buyers. Over the years, Ant Group has grown to become one of the world's leading open Internet platforms.
Through technological innovation, Ant Group supports its partners in providing inclusive, convenient digital life and digital financial services to consumers and SMEs. In addition, it has been introducing new technologies and products to support the digital transformation of industries and facilitate industrial collaboration. Working together with global partners, the company enables merchants and consumers to make and receive payments and remit around the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305020027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom